NZMS Diabetes Launches the next-generation Dexcom CGM, Dexcom G7!
Posted Oct 27, 2022.
New Zealand first in the southern hemisphere to launch Dexcom G7 Continuous Glucose Monitoring System to improve diabetes management for Kiwis
Latest technology becomes available as November marks World Diabetes Day and New Zealand Diabetes Action Month
AUCKLAND, New Zealand – Thursday Oct. 27, 2022 – Dexcom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, and its New Zealand subsidiary New Zealand Medical and Scientific Ltd (NZMS) Diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System is now available for people with diabetes aged two years and older in New Zealand – marking the first major milestone in the availability of the revolutionary new technology in the southern hemisphere.
“We are very excited to be one of the first launch countries in the world of the powerful Dexcom G7 as New Zealand can often be overlooked by global emerging medical technologies,” said Kirstin Brown, Country Manager for NZMS Diabetes. “Dexcom in their product development process of G7 have listened to people living with Type 1 and Type 2 diabetes of all ages and their caregivers about the CGM features they need to allow them to focus more on their everyday lives and less on managing diabetes. We now have a solution that will gain results faster, longer, and with greater accuracy than ever before—all with a smaller, more discreet wearable device.”1
“Since its predecessor, Dexcom G6, came to market, we’ve eliminated over 15 billion fingerpricks‡ and helped improve the lives of more than 1.25 million people with diabetes around the world. We’re thrilled to begin the global rollout of Dexcom G7, our next-generation CGM technology, that vastly improves upon what everyone loves about G6,” said Kevin Sayer, chairman, president and CEO of Dexcom.
“Dexcom has been humbled by the commitment Kiwis have shown the G7 predecessor Dexcom G6 – especially in a non-reimbursed market. With Dexcom’s recent acquisition of NZMS, they are now able to invest in more than just diabetes management and now advocate for the improved quality of life for Kiwis,” said Brown.
“Since the launch of the G6 locally in 2020 we have been thrilled to support increasingly more New Zealanders gain insight, choices, connectivity to their care teams and partner devices and ultimately increased ownership of their care. This has helped them achieve greater glycaemic control, lowered HbA1c, increased time spent in target glucose range, and reduced time spent in hyper or hypoglycaemia2-6. It has also eliminated an estimated 40 million fingerpricks‡ and counting here in New Zealand alone.”
How the new Dexcom G7 works
Dexcom G7 offers a powerful yet simple way to help users gain greater control of their diabetes, so they can manage their diabetes more confidently each day. Its low-profile, all-in-one wearable warms up faster than any of our other CGMs on the market,* sending real-time glucose readings automatically to a compatible smart device§ or receiver, with no fingerpricks† or burdensome scanning required.
Dexcom G7 builds on the trusted performance of Dexcom CGM, which is clinically proven to lower hbA1c and reduce hyper- and hypoglycaemia.||,2 Its customisable alerts can warn of high or low glucose levels and help users spend more time in range.||,6 Industry-leading remote monitoring and reporting capabilities also allow users to stay connected with their loved ones and care teams anytime, anywhere.¶
NEW features with Dexcom G7:
• 60% smaller, all-in-one, discreet wearable, developed in partnership with Verily
• 30-minute sensor warm up, fastest of our Dexcom CGMs on the market*
• 12-hour grace period to replace finished sensors for a more seamless transition between sessions
• Redesigned and simplified mobile app with Dexcom Clarity integration#,**
• Improved alert settings for enhanced discretion
• Redesigned optional receiver that is smaller, with a more vibrant, easier to read display
Dexcom G6 features included with the new Dexcom G7:
• No fingerpricks†, scanning or calibration
• Real-time glucose readings sent automatically to a compatible display device§
• Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older and upper buttocks for 2-6 year olds
• Integration with the world’s largest connected CGM ecosystem
• Remote monitoring, enabling users to share glucose data with up to 10 followers¶
• Proven Dexcom accuracy and performance1
Dexcom is also working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as possible.
To learn more about Dexcom G7, click here.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom, visit dexcom.com/en-NZ